Respiratory Syncytial Virus (RSV) Market 2024: Industry Size, Company Share And Distribution Share Data And Analysis
"The
Latest Research Report OpportunityAnalyzer: Respiratory Syncytial
Virus (RSV) - Opportunity Analysis and Forecasts to 2024 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Respiratory Syncytial Virus (RSV) Market
Human respiratory syncytial virus
(RSV) is an enveloped, single-stranded, negative-sense ribonucleic
acid (RNA) pneumovirus belonging to the family of Paramyxoviridae.
The virus was discovered in 1956, first as an isolate from a
laboratory chimpanzee displaying symptoms of the common cold, and
later from infants suffering from respiratory disease. RSV can cause
upper respiratory tract infections (the common cold) and is the most
important cause of lower respiratory tract infections, such as
bronchiolitis and pneumonia, in infants. RSV is also an important
cause of hospitalizations and deaths in elderly adults.
Today, Medimmunes Synagis
(palivizumab) is the only licensed intervention for the prevention of
RSV in infants at a high risk of severe infection. This humanized,
mouse monoclonal antibody (mAb) was first approval in 1998, and while
it is an efficacious prophylactic intervention, its short 20-day
half-life necessitates monthly dosing during the RSV season.
Moreover, the high cost of Synagis limits its use to certain
subgroups of infants who are at high risk of severe RSV infection,
and it is not indicated for use in elderly adults, leaving a key
population of high-risk individuals unprotected. Furthermore, due to
the absence of effective RSV-specific antivirals, the treatment of
RSV infections is largely restricted to a number of supportive
treatment options. GlobalData projects the global RSV marketplace -
which, for the purposes of this report, comprises the seven major
pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK,
Japan) - to experience unprecedented growth from 2014-2024, driven by
the arrival of novel approaches to prevention and management of RSV.
Highlights
Key Questions Answered
- Based on interviews with key
opinion leaders (KOLs), GlobalData has identified the major unmet
needs in the RSV marketplace. Will the leading pipeline agents fulfil
these unmet needs during the forecast period (2014-2024)?
- What research and development
(R&D) strategies will companies leverage to compete in the future
RSV marketplace?
- Which patient population(s) are
most likely to be targeted by novel RSV prophylactic and therapeutic
agents?
- What clinical and commercial
factors are likely to influence RSV product uptake in the 7MM?
Get Sample Copy Of This Report
@ https://www.marketresearchreports.biz/sample/sample/699481
Key Findings
- The global RSV marketplace -
which, for the purposes of this report, encompasses the sales of
products for the prevention or treatment of RSV in the 7MM - was
worth approximately $640m in 2014. GlobalData projects the market to
surpass $2.3bn in sales by 2024, at a compound annual growth rate
(CAGR) of 29.9% from 2014-2024. The sales are projected to originate
predominantly from the US (a 62% market share), followed distantly by
the 5EU (a 29% market share).
- The anticipated arrival of novel
prophylactic mAbs that boast improved dosing criteria compared with
Synagis, led by MedImmunes MEDI8897, will be a principal driver of
RSV market growth across the 7MM. The licensure of the first adult
vaccine to offer protection against RSV, Novavaxs RSV-F Vaccine, will
also stimulate rapid growth in a previously untapped segment of the
marketplace.
- A persistent lack of patient and
physician awareness of RSV in adult patients - specifically the
infections substantial impact on morbidity and mortality in the
elderly - will serve as a key impediment to market growth from
2014-2024.
Scope
- Overview of RSV infections,
including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and current management strategies.
- Topline RSV market revenue from
2014-2024. Annual cost of therapy (ACOT) and major pipeline product
sales in this forecast period are included.
- Key topics covered include
current treatment options, unmet needs and opportunities, and the
drivers and barriers affecting RSV product sales in the 7MM.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, synopses of innovative early-stage projects, and
detailed analysis of late-stage pipeline products.
- Analysis of the current and
future market competition in the global RSV market. Insightful review
of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global RSV market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the RSV market in the
future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments,
and strategic partnerships.
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/699481
3 Disease Overview 22
3.1 Etiology and Pathophysiology
22
3.1.1 Etiology 22
3.1.2 Pathophysiology 26
3.2 Symptoms and Prognosis 28
3.2.1 Symptoms 28
3.2.2 Prognosis 30
3.3 Quality of Life 31
3.4 Disease Management 31
3.4.1 Diagnosis of RSV Infection
32
3.4.2 Prevention of RSV Infection
34
3.4.3 Treatment of RSV Infection
37
4 Epidemiology 40
4.1 Disease Background 40
4.2 Risk Factors and Comorbidities
41
4.3 Global Trends 43
4.3.1 Preterm Infants and Children
Born Preterm and Survived to Two Years of Age 44
4.3.2 Infants with Neonatal CLD 44
4.3.3 Children with
Hemodynamically Significant Congenital Heart Disease 45
4.3.4 Children with Congenital
Respiratory or Neuromuscular Diseases That Compromise Respiratory
Function 45
4.3.5 Third-Trimester Pregnant
Women 46
4.3.6 Hospitalizations for RSV
Infection 47
4.4 Forecast Methodology 48
4.4.1 Sources Used 54
4.4.2 Sources Not Used 62
4.4.3 Forecast Assumptions and
Methods 63
4.5 Epidemiological Forecast for
RSV Infection (2014-2024) 72
4.5.1 Risk Groups for Severe RSV
Infection in Children Less than Two Years 72
4.5.2 Preterm Births 78
4.5.3 Neonatal CLD 79
4.5.4 Third-Trimester Pregnant
Women 80
4.5.5 RSV Hospitalizations in
Children 81
4.6 Discussion 83
4.6.1 Epidemiological Forecast
Insight 83
4.6.2 Limitations of the Analysis
85
4.6.3 Strengths of the Analysis 85
5 Current Treatment Options 87
5.1 Overview 87
5.2 Product Profiles - RSV
Prophylactics 89
5.2.1 Synagis (palivizumab) 89
5.3 Product Profiles - RSV
Therapeutics 95
5.3.1 Virazole (aerosolized
ribavirin) 95
5.4 Other Supportive Measures 101
6 Unmet Needs and Opportunities
103
6.1 Overview 103
6.2 Effective Therapeutic
Interventions 105
6.2.1 Unmet Need 105
6.2.2 Gap Analysis 106
6.2.3 Opportunity 108
6.3 Prophylactic Vaccines 109
6.3.1 Unmet Need 109
6.3.2 Gap Analysis 111
6.3.3 Opportunity 113
6.4 A Prophylactic mAb with an
Increased Half-Life 114
6.4.1 Unmet Need 114
6.4.2 Gap Analysis 115
6.4.3 Opportunity 116
6.5 Point-of-care Testing for RSV
in Adult Patients 117
6.5.1 Unmet Need 117
6.5.2 Gap Analysis 118
6.5.3 Opportunity 119
6.6 Increased Awareness of RSV
Infections in Adults 119
6.6.1 Unmet Need 119
6.6.2 Gap Analysis 120
6.6.3 Opportunity 120
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment